X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA FRESENIUS KABI ONCO. ASTRAZENECA PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 161.7 22.1 730.8% View Chart
P/BV x 25.1 3.1 806.8% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
FRESENIUS KABI ONCO.
Mar-13
ASTRAZENECA PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,285176 730.1%   
Low Rs63479 807.6%   
Sales per share (Unadj.) Rs189.637.7 503.1%  
Earnings per share (Unadj.) Rs-0.25.1 -4.0%  
Cash flow per share (Unadj.) Rs3.86.7 57.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.642.5 161.3%  
Shares outstanding (eoy) m25.00158.23 15.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.13.4 149.9%   
Avg P/E ratio x-4,712.725.0 -18,862.6%  
P/CF ratio (eoy) x249.618.9 1,318.7%  
Price / Book Value ratio x14.03.0 467.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,98820,135 119.1%   
No. of employees `0001.61.2 135.3%   
Total wages/salary Rs m1,605703 228.2%   
Avg. sales/employee Rs Th3,040.25,176.2 58.7%   
Avg. wages/employee Rs Th1,029.2610.4 168.6%   
Avg. net profit/employee Rs Th-3.3699.6 -0.5%   
INCOME DATA
Net Sales Rs m4,7405,963 79.5%  
Other income Rs m9218 511.7%   
Total revenues Rs m4,8325,981 80.8%   
Gross profit Rs m-1301,430 -9.1%  
Depreciation Rs m101258 39.2%   
Interest Rs m0-26 0.0%   
Profit before tax Rs m-1391,216 -11.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m139-68 -204.0%   
Tax Rs m5342 1.5%   
Profit after tax Rs m-5806 -0.6%  
Gross profit margin %-2.724.0 -11.4%  
Effective tax rate %-3.728.1 -13.0%   
Net profit margin %-0.113.5 -0.8%  
BALANCE SHEET DATA
Current assets Rs m2,7265,102 53.4%   
Current liabilities Rs m2,4352,385 102.1%   
Net working cap to sales %6.145.6 13.5%  
Current ratio x1.12.1 52.4%  
Inventory Days Days74150 49.2%  
Debtors Days Days41113 36.0%  
Net fixed assets Rs m1,0355,148 20.1%   
Share capital Rs m50158 31.6%   
"Free" reserves Rs m9426,556 14.4%   
Net worth Rs m1,7166,732 25.5%   
Long term debt Rs m0952 0.0%   
Total assets Rs m4,15610,388 40.0%  
Interest coverage xNM-45.8-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.10.6 198.7%   
Return on assets %-0.17.5 -1.6%  
Return on equity %-0.312.0 -2.5%  
Return on capital %014.6 0.0%  
Exports to sales %5.774.5 7.7%   
Imports to sales %6.524.8 26.1%   
Exports (fob) Rs m2704,441 6.1%   
Imports (cif) Rs m3061,477 20.7%   
Fx inflow Rs m3755,298 7.1%   
Fx outflow Rs m4701,772 26.5%   
Net fx Rs m-963,525 -2.7%   
CASH FLOW
From Operations Rs m-81,274 -0.6%  
From Investments Rs m-146-1,204 12.1%  
From Financial Activity Rs m862-196 -439.7%  
Net Cashflow Rs m709-126 -561.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 81.0 92.6%  
Indian inst/Mut Fund % 0.3 0.3 100.0%  
FIIs % 15.7 9.6 163.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 9.1 100.0%  
Shareholders   12,856 42,599 30.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PANACEA BIOTECH  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS